Presented by The New York Academy of Sciences

The biologics field remains a flourishing drug discovery and development area currently with over 200 products on the market, among which 35 monoclonal antibody therapeutics have been approved by the FDA and hundreds of candidates are in commercial development pipeline. Technology plays a pivotal role in developing next-generation biologics. For example, molecular engineering technologies have been successfully applied to optimize the drug attributes by modifying the molecular constitution of biologics. The recent US approval of the antibody-drug conjugate Kadcyla (also called T-DM1) for the treatment of breast cancer and Japan approval of glyco-engineered antibody mogamulizumab for T cell leukemia-lymphoma are two good examples. In addition, new technologies impact other aspects of biologics discovery and development such as manufacturing and delivery of drug substances. We will start the symposium with an overview of technological advancement in the biologics field, followed by an in-depth discussion on three key areas: 1) Innovative technologies applied to the discovery of new therapeutic antibodies; 2) New technologies applied to elucidating the in vivo mechanisms of therapeutic proteins; 3) New manufacturing and delivery technologies. Our goal is to review a number of cutting-edge technologies being developed both in the biotech/ pharmaceutical industry as well as in academic institutions and address the challenges and opportunities around the application of new technologies toward the development of the next generation biologics.

May 20, 2014

Register Today!